All Comments by Stefan Lichtenthaler

  1. Merck Pulls Plug on Phase 2/3 BACE Inhibitor Trial
  2. New MO for Purported Anti-Amyloid Drug: Shielding APP from BACE?
  3. Paper Alert: Verubecestat Preclinical and Phase 1 Data Published
  4. Partners in Crime: APP Fragment and Endosomal Protein Impair Endocytosis
  5. Centrally Delivered BACE1 Inhibitor Activates Microglia, and Reverses Amyloid Pathology and Cognitive Deficit in Aged Tg2576 Mice.
  6. β-Secretase BACE1 regulates hippocampal and reconstituted M-currents in a β-subunit-like fashion.
  7. Pharmacological inhibition of BACE1 impairs synaptic plasticity and cognitive functions.
  8. Knock-in of human BACE1 cleaves murine APP and reiterates Alzheimer-like phenotypes.
  9. Bace1 and Neuregulin-1 cooperate to control formation and maintenance of muscle spindles.
  10. Lilly Halts Phase 2 Trial of BACE Inhibitor Due to Liver Toxicity
  11. β-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment.
  12. The lipoprotein receptor LR11 regulates amyloid beta production and amyloid precursor protein traffic in endosomal compartments.
  13. Interaction of the cytosolic domains of sorLA/LR11 with the amyloid precursor protein (APP) and beta-secretase beta-site APP-cleaving enzyme.
  14. Nicastrin—A DAPper Role in γ-Secretase
  15. Follow the Leader to Higher BACE Levels